Zevra Therapeutics (ZVRA) Financial Statements & Analysis

Zevra Therapeutics (ZVRA) Income Statement

Zevra Therapeutics reported revenue of $106.47M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 350.9% from $23.61M a year earlier. Net income was $83.23M, a net margin of 78.2%. Gross margin was 84.5% and operating margin -4.0%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $39.66M, up 53.3% from the same quarter a year earlier.

Zevra Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Zevra Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	106.47	23.61	27.46	10.16	28.65	13.29	12.84	0.00	0.00
Cost of Revenue	16.48	7.42	2.17	0.22	2.06	1.31	2.95	0.32	0.34
Gross Profit	89.99	16.20	25.29	10.12	26.59	11.98	9.89	-0.32	-0.34
Operating Expenses
Research & Development	12.74	42.10	39.81	19.23	9.64	8.84	19.42	41.76	20.59
Selling, General & Administrative	77.62	54.87	34.31	15.61	9.23	7.92	10.82	12.51	12.77
Operating Expenses	94.22	103.20	74.89	52.62	18.86	17.59	30.23	54.27	33.37
Operating Income	-4.23	-87.00	-49.60	-42.51	7.73	-5.61	-20.34	-55.90	-33.37
Other Income/Expense
Interest Income	6.95	2.18	4.54	0.76	0.26	0.09	0.31	0.42	0.37
Interest Expense	7.98	7.35	1.50	-0.34	-0.38	7.09	6.51	7.09	7.34
Other Income/Expense	90.91	2.04	0.52	0.18	-16.25	-7.19	-4.21	-0.69	-10.06
Income
Income Before Tax	86.68	-90.14	-46.05	-26.81	-8.52	-12.79	-24.54	-56.59	-43.43
Income Tax Expense	3.45	15.37	0.00	0.79	-0.03	-0.03	-0.02	-0.13	-0.04
Net Income	83.23	-105.51	-46.05	-41.54	-62.90	-12.76	-24.52	-56.47	-43.39
Net Income - Continuous Operations	83.23	-105.51	-46.05	-26.77	-8.56	-12.76	-24.52	-56.47	-43.39
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	98.71	-76.40	-43.54	-23.96	7.99	-5.43	-17.73	-53.94	-33.03
EBIT	-4.23	-82.79	-44.55	-24.90	7.73	-4.78	-	-	-
Depreciation & Amortization	4.05	6.24	0.77	0.94	0.26	0.27	0.30	0.32	0.34
Earnings Per Share
Basic EPS	1.00	-2.00	-1.00	-1.00	-2.00	-3.00	-13.00	-50.00	-47.00
Diluted EPS	1.00	-2.00	-1.00	-1.00	-2.00	-3.00	-13.00	-50.00	-47.00
Basic Shares Outstanding	55.31	46.25	35.45	34.49	29.77	3.98	1.85	1.12	0.92
Diluted Shares Outstanding	57.26	46.25	35.45	34.49	29.77	3.98	1.85	1.12	0.92

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Zevra Therapeutics Financial Statements

What was Zevra Therapeutics's revenue in fiscal 2025?

Zevra Therapeutics reported revenue of $106.47M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 350.9% from $23.61M a year earlier.

Is Zevra Therapeutics profitable?

Yes. Zevra Therapeutics earned net income of $83.23M in fiscal 2025, a net margin of 78.2%. In fiscal 2024 it lost $105.51M.

What is Zevra Therapeutics's operating margin?

Zevra Therapeutics's operating income was −$4.23M on revenue of $106.47M in fiscal 2025, an operating margin of -4.0%, compared with -368.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition